Diagnostics company Sekisui Diagnostics revealed on Tuesday that the Acucy Influenza A&B Test Class II assay has passed the US Food and Drug Administration's (FDA) 510(k) clearance as well as the CLIA Waiver for use on the Acucy Reader in either the point-of-care or laboratory setting to help improve patient outcomes, maximize clinical efficiencies and reduce operational budgets.
The company added that the Acucy Influenza A&B Test is intended for the rapid, qualitative detection of influenza A and B viral nucleoprotein antigens from both nasal and nasopharyngeal swabs. The Influenza A&B Test combined with the Reader provides clinicians with standardized and definitive result interpretation.
Upon clearance, the Acucy Influenza A&B test expands the company's flu portfolio to include all three commonly used modalities in the CLIA ((Clinical Laboratory Improvement Amendments)) Waived environment: OSOM Ultra Flu A&B Test (manual read lateral flow), Acucy Influenza A&B Test (point-of-care reader) and the Silaris Influenza A&B Test (molecular point-of-care).
Since the launch of rapid molecular tests and the 2018 FDA Flu reclassification focusing on the improved performance of on market rapid immunoassays, the clinicians are now more confident in test results and therefore better able to provide direct therapy, said the company.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT